Denali Therapeutics Inc
DNLI
Market Cap$1.92B
Close$
$0.77
94.5% downside
Current Fair Value
94.5% downsideOvervalued by 94.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.92 Billion |
|---|---|
| Enterprise Value | $1.92 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.57 |
| Beta | 1.49 |
| Outstanding Shares | 171,222,030 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.99 |
|---|---|
| PEG | -16.31 |
| Price to Sales | - |
| Price to Book Ratio | 2.32 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.72 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts